Biotech中國Court CasesInvalidationPharma
2018年11月23日

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses what is considered allowable claim scope around sequences.

It is well known that China has strict requirements when it comes to adequate written description and support in the specification. Chinese Patent Law Article 26(4) says that “all claims must be supported by the description and shall define the extent of the patent protection sought for in a clear and concise manner.”

In the unpredictable arts, such as chemistry and biology, the breadth of protection is highly dependent on the number and scope of the specific examples in the specification. The resultant narrow claims that are often issued in China are easy to design-around, thus making Chinese patents less attractive for biotech inventions with few actual examples.

Invalidation Request: Novozymes CN98813338.5

We summarize a Top 10 IP Cases of 2016 regarding an invalidation request of Novozymes’ Chinese invention patent (CN98813338.5) by Jiangsu Boli Biological Products Co. Ltd. Novozyme’s patent relates to an isolated glucoamylase with improved thermal stability and many uses, such as converting starch into glucose. The claims were written in a way that included a functional limitation (having “glucoamylase activity”) plus a scope defined in one or more of the following ways: “comprising” a SEQ ID, consisting of a SEQ ID plus 99% homology, and source, e.g., derived from a particular strain.

For support, the specification described two sequences, SEQ ID NO: 7 and 14, both of which were isolated enzymes from a strain of the filamentous fungus T. emersonii that had glucoamylase activity.

The court rejected claims that merely defined the enzyme using either open-ended “comprising” language or percent homology language, saying the scope was too open-ended and not supported by the examples. However, the court allowed claims that further narrowed the claim to cover sequences made by a particular strain. The court reasoned that only a very narrow set of sequences could possibly be made from the strain, and thus the limitation was adequately supported by the two examples.

Practice Points

As a practice point, consider multiple ways of defining your invention (e.g., “source” was the winner here, but the possibilities depend on the situation). There are many creative ways to define your invention: the more examples showing the “reasonable, predictable scope” of the active species, the better. Ideally, focus on describing how the function is linked to the structure or other properties (e.g., structural and functional domains of a polypeptide, source, method of preparation, physicochemical properties, etc.).

Sources: lungtin unitalen

Jennifer Che, J.D. is a US Patent Attorney and Vice President and Partner at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

[email protected]

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

2022年6月30日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

我們過去活動

Top crossarrow-right